Browsing tag:

Irinotecan


Ewing sarcoma tumors disappeared and did not return in more than 70% of mice treated with combination therapy that included Irinotecan and Temozolomide, which are experimental agents developed to fight breast cancer, reported St. Jude Children’s Research Hospital scientists. The study will appear in the November 6 edition of the scientific journal Cell Reports. The treatment paired two chemotherapy drugs currently[…]

Read More

On August 3, 2012, the United States Food and Drug Administration (USFDA) approved ziv-aflibercept injection ( Zaltrap, made by Sanofi and Regeneron Pharmaceuticals, Inc.) for use in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following treatment with an[…]

Read More

Elacridar, an ABCB1 modulator acting as a drug transporter, has been proven to have beneficial effects on the resistance of cancer cells to standard chemotherapeutic agents. This unique delivery system makes resistant cancers more susceptible to standard chemotherapeutic regimen. A study done by Ho Lun Wong et al showed beneficial results when Elacridar was used[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service